Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 24, 2021; 12(8): 702-711
Published online Aug 24, 2021. doi: 10.5306/wjco.v12.i8.702
PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report
Guillermo Arturo Valencia, Patricia Rioja, Zaida Morante, Jhajaira M Araujo, Heberth Daniel Vallejos, Henry Guerra, Henry L Gomez
Guillermo Arturo Valencia, Patricia Rioja, Zaida Morante, Henry L Gomez, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima 15000, Peru
Jhajaira M Araujo, Escuela de Medicina Humana, Universidad Privada San Juan Bautista, Lima 15067, Peru
Heberth Daniel Vallejos, Department of Medical Oncology, Russian Scientific Center of Radiology and Radiotherapy, Konkovo 117485, Moscow, Russia
Henry Guerra, Department of Pathology, Instituto Nacional de Enfermedades Neoplásicas, Lima 15000, Peru
Author contributions: Valencia GA wrote the paper and collected data; All the authors analyzed the data and approve the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this manuscript, also the accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Guillermo Arturo Valencia, MD, Medical Assistant, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Angamos Este Avenue 2520, Surquillo, Lima 15000, Peru. guillermo.valencia.mesias@gmail.com
Received: May 10, 2021
Peer-review started: May 10, 2021
First decision: June 5, 2021
Revised: June 18, 2021
Accepted: July 12, 2021
Article in press: July 12, 2021
Published online: August 24, 2021
Core Tip

Core Tip: This case report evaluates the detection of a PIK3CA mutation in liquid biopsy and tumor tissue in a patient with locally-advanced triple-negative breast cancer after receiving conventional oncological therapy and its association with early relapse and progression disease. This case highlights the importance of detecting the PIK3CA mutation as a potential biomarker of early relapse. In addition, the PIK3CA mutation could lead to additional interventions to detect metastatic disease earlier in the follow-up. There is limited information of liquid biopsy studies after surgery. Furthermore, there is very limited data about trials of PIK3CA mutations in Peruvian patients with non-metastatic breast cancer.